SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman caught up with Proactive London's Andrew Scott following the news they've agreed a deal with Dutch firm Winclove Probiotics to develop a food supplement to combat psoriasis.
The pair plan to carry out a human study on mild to moderate sufferers of the skin condition, which will take between 12 and 18 months ahead of commercialisation and launch of the probiotic.